Prothena Corp Public (PRTA) Cash from Financing Activities (2012 - 2026)

Prothena Corp Public's (PRTA) quarterly Cash from Financing Activities came in at -$6.9 million in Q1 2026, down 14370.83% year-on-year from N/an in Q1 2025, and down 40758.82% quarter-over-quarter from -$17000.0 in Q3 2025.

Prothena Corp Public (PRTA) Cash from Financing Activities (2012 - 2026) Analysis & Trends

Prothena Corp Public's Cash from Financing Activities history runs 15 years deep, the most recent figure standing at -$6.9 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 14370.83% year-over-year to -$6.9 million in Q1 2026; TTM through Mar 2026 was -$7.0 million, a 1150.3% decrease from a year earlier, with the FY2025 full-year figure at -$139000.0, down 108.94% from the prior year.
  • Cash from Financing Activities eased to -$6.9 million in Q1 2026 per PRTA's latest filing, from -$17000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $220.8 million in Q4 2022 and bottomed at -$6.9 million in Q1 2026.
  • The 5-year median for Cash from Financing Activities is $659500.0 (2023), against an average of $17.6 million.
  • Across the five-year window, Cash from Financing Activities surged 12351.49% in 2022 and slumped 14370.83% in 2026, its largest moves.
  • Year by year, Cash from Financing Activities stood at $220.8 million in 2022, then slumped by 99.78% to $483000.0 in 2023, then tumbled by 112.22% to -$59000.0 in 2024, then surged by 71.19% to -$17000.0 in 2025, then plunged by 40758.82% to -$6.9 million in 2026.
  • Per Business Quant, the three latest PRTA Cash from Financing Activities figures stand at -$6.9 million (Q1 2026), -$17000.0 (Q3 2025), and -$74000.0 (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 30.14 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 68.63 Mn
4 NuCana 279.75 Bn 279.75 Bn - 9,311.16
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 238.74 Mn
10 Prothena Corp Public 458.13 Mn 128.67 Mn - -6.95 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -6.95 Mn
Mar 31, 2026 -6.95 Mn
Sep 30, 2025 -17,000.00
Sep 30, 2025 -17,000.00
Jun 30, 2025 -74,000.00
Jun 30, 2025 -74,000.00
Mar 31, 2025 -48,000.00
Mar 31, 2025 -48,000.00
Dec 31, 2024 -59,000.00
Dec 31, 2024 -59,000.00
Sep 30, 2024 333,000.00
Sep 30, 2024 333,000.00
Jun 30, 2024 444,000.00
Jun 30, 2024 444,000.00
Mar 31, 2024 836,000.00
Mar 31, 2024 836,000.00
Dec 31, 2023 483,000.00
Dec 31, 2023 483,000.00
Sep 30, 2023 2.71 Mn
Sep 30, 2023 2.71 Mn